Madrigal to Present Rezdiffra Data in Denver
The drugmaker will share new real-world research on its MASH medication at a medical conference starting November 5.
Updated on Nov. 2, 2026 in Diabetes
Madrigal Pharmaceuticals will present new real-world research on Rezdiffra, a once-daily oral medication also known as resmetirom, at a medical conference in Denver beginning November 5. The presentations include 13 abstracts from its RESONANCE real-world evidence program at the AASLD Liver Meeting, November 5-9.
Why it matters
Rezdiffra was the first medication approved for MASH in the United States and Europe, making its real-world performance a closely watched measure of its use beyond clinical trials. The research is relevant to Madrigal's commercialization strategy.
The analyses draw on data from more than 12,000 patients and examine changes in noninvasive liver health measures over as long as 12 months, with 91% of patients on the 100-milligram dose showing improved or stable liver stiffness at one year. Confirmatory clinical research is still ongoing, and continued approval may depend on verification of clinical benefit.
The players
Madrigal Pharmaceuticals
Madrigal Pharmaceuticals is a Conshohocken, Pennsylvania-based drugmaker focused on liver disease, and it developed Rezdiffra as the first approved treatment for MASH.
The details
Rezdiffra targets thyroid hormone receptor beta in the liver and is approved for adults with noncirrhotic MASH and moderate to advanced liver fibrosis, stages F2 to F3. It is not approved for patients with cirrhosis, and the Phase 3 MAESTRO-NASH trial met its primary endpoints for liver fibrosis improvement and MASH resolution.
Timeline
November 5: Medical conference in Denver begins with Madrigal presentations.
November 5-9: AASLD Liver Meeting, where Madrigal presents 13 RESONANCE abstracts.
Big Picture
Rezdiffra's original approval as the first MASH treatment in the United States set the benchmark that these real-world results now build upon. Its ongoing confirmatory research will determine whether early liver-health gains translate into lasting clinical benefit.
Patients with noncirrhotic MASH and moderate to advanced fibrosis may find this real-world evidence useful when discussing treatment options with their doctors. Rezdiffra is not approved for patients with cirrhosis, so eligibility should be confirmed with a clinician.
The takeaway
Real-world data from more than 12,000 patients will help clarify how MASH treatments perform outside controlled trials. Readers with liver disease should discuss eligibility and monitoring with their healthcare provider.
What happens next
Madrigal's RESONANCE abstracts are scheduled for presentation at the AASLD Liver Meeting from November 5 to 9, 2026.
Further reading
Explore more on Diabetes for context on metabolic liver conditions.
Source note: This article includes information reported by MyChesCo.
